APOH is increased in the plasma and liver of type 2 diabetic patients with metabolic syndrome

Atherosclerosis

Volumn 209, Issue 1, 2010, Pages 201-205

  Castro, Antoni ^a,c   Lázaro, Iolanda ^a,c   Selva, David M ^b,c   Céspedes, Ela ^a   Girona, Josefa ^a,c   NuriaPlana ^a,c   Guardiola, Montse ^a,c   Cabré, Anna ^a,c   Simó, Rafael ^b,c   Masana, Lluís ^a,c  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Adipokines; APOH; Arteriosclerosis; Lipids; Oxidation; Type 2 diabetes

Indexed keywords

AMINO ACID; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; LEUCINE; LIPOPROTEIN; MESSENGER RNA; PROTEIN ANTIBODY; RETINOL BINDING PROTEIN 4; SERINE; TRIACYLGLYCEROL; TRYPTOPHAN; VALINE;

ADIPOSE TISSUE; ADULT; AGED; AMINO ACID ANALYSIS; ARTICLE; BARIATRIC SURGERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATORY DISEASE; INSULIN RESISTANCE; LIVER; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN VARIANT; SUBCUTANEOUS TISSUE;

AGED; BETA 2-GLYCOPROTEIN I; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LIVER; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK;

EID: 77049117732     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.09.072     Document Type: Article

References (22)

1. Day J.R., O'Hara P.J., Grant F.J., et al. Molecular cloning and sequence analysis of the cDNA encoding human apolipoprotein H (b2-glycoprotein I). Int J Clin Lab Res 21 (1992) 256-263
2. Polz E., and Kostner G.M. The binding of beta2-glycoprotein-I to human serum lipoproteins. Distribution among density fractions. FEBS Lett 102 (1979) 183-186
3. Kamboh M.I., Sanghera D.K., and Mehdi H. Single nucleotide polymorphisms in the coding region of the apolipoprotein H (beta2-glycoprotein I) gene and their correlation with the protein polymorphism, anti-beta2glycoprotein I antibodies and cardiolipin binding: description of novel haplotypes and their evolution. Ann Hum Genet 68 (2004) 285-299
4. Takada D., Ezura Y., and Ono S. Apolipoprotein H variant modifies plasma triglyceride phenotype in familial hypercholesterolemia: a molecular study in an eight-generation hyperlipidemic family. J Atheroscler Thromb 10 (2003) 79-84
5. 2-Glycoprotein I and its clinical significance: from gene sequence to protein levels. Autoimmun Rev 6 (2007) 547-552
6. Cassader M., Ruiu G., Gambino R., Veglia F., and Pagano G. Apolipoprotein H levels in diabetic subjects: correlation with cholesterol levels. Metabolism 46 (1997) 522-525
7. Crook M., Chng S.I., Lumb P., and Reid F. Serum apolipoprotein H and its relationship to blood pressure, serum lipids, fasting plasma glucose and insulin in normal individuals. Ann Clin Biochem 38 (2001) 494-498
8. Zahedi R.G., Summers L.K., Lumb P., Chik G., and Crook M.A. The response of serum apolipoprotein H to an oral fat load. Ann Clin Biochem 41 (2004) 330-334
9. George J., Harats D., Gilburd B., et al. Immunolocalization of beta2-glycoprotein I (APOH) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 99 (1999) 2227-2230
10. Niessen H.W., Lagrand W.K., Rensink H.J., et al. Apolipoprotein H, a new mediator in the inflammatory changes ensuring in jeopardised human myocardium. J Clin Pathol 53 (2000) 863-867
11. Roman M.J., Shanker B.A., Davis A., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349 (2003) 2399-2406
12. El-Magadmi M., Bodill H., Ahmad Y., et al. Systemic lupus erythematosus. An independent risk factor for endothelial dysfunction in women. Circulation 110 (2004) 399-404
13. Esdaile J.M., Abrahamowicz M., Grodzicky T., et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44 (2001) 2331-2337
14. Lopez L.R., Salazar-Paramo M., Palafox-Sanchez C., et al. Oxidized low-density lipoprotein and beta2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis. Lupus 15 (2006) 80-86
15. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
16. Schumaker V.N., and Puppione D.L. Sequential flotation ultracentrifugation. Meth Enzymol 128 (1986) 155-170
17. Cho Y.M., Youn B.S., Lee H., et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diab Care 29 (2006) 2457-2461
18. Cabré A., Lázaro I., Girona J., et al. Retinol-binding protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease in type 2 diabetes. J Intern Med 262 (2007) 496-503
19. 2-glycoprotein I) gene affects plasma apolipoprotein H concentrations. Hum Genet 105 (1999) 63-71
20. Palomo I., Pereira J., Alarcón M., et al. Val/Leu247 and Trp/Ser316 polymorphisms in beta 2 glycoprotein I and their association with thrombosis in unselected Chilean patients. Clin Rheumatol 26 (2007) 302-307
21. Cabré A., Lázaro I., Girona J., et al. Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis 195 (2007) e150-e158
22. Gustafson B., Hammarstedt A., Andersson C.X., and Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 27 (2007) 2276-2283